Neurol. praxi. 2014;15(5):268-272

Polymyositis

prof. MUDr. Jiří Vencovský, DrSc.
Revmatologický ústav, Praha

Polymyositis is a rare disease manifesting with muscle weakness located particularly to proximal parts of extremities. A number of patients have also extramuscular manifestations, such as dysphagia, interstitial lung disease or arthritis. Muscle biopsy shows endomysial inflammatory infiltrate and MHC class I hyperexpression on muscle cells, EMG displays myogenic findings, and usually CK and/or other muscle enzyme levels are elevated. Detection of serum autoantibodies is diagnostically and prognostically helpful since some of them are specific for myositis and typical for particular clinical situations, such as antisynthetase syndrome. Many patients with PM respond to glucocorticoid or immunosuppressive treatment; full resistance prompts to diagnosis verification.

Keywords: myositis, inflammatory myopathy, classification, autoantibodies, treatment

Published: November 18, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vencovský J. Polymyositis. Neurol. praxi. 2014;15(5):268-272.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Albayda J, Mammen AL. Is statin-induced myositis part of the polymyositis disease spectrum? Curr Rheumatol Rep 2014; 16(8): 433. doi: 10.1007/s11926-014-0433-8. Go to original source... Go to PubMed...
    2. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-347. Go to original source... Go to PubMed...
    3. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-407. Go to original source... Go to PubMed...
    4. Bunch TW. Prednisone and azathioprine for polymyositis. Arthritis Rheum 1981; 24: 45-48. Go to original source... Go to PubMed...
    5. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329(27): 1993-2000. Go to original source... Go to PubMed...
    6. Furst DE, Amato AA, Iorga ŞR, Gajria K, Fernandes AW. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 2012; 45(5): 676-683. Go to original source... Go to PubMed...
    7. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, Vencovsky J, de Visser M, Hughes RA. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14(5): 337-345. Go to original source... Go to PubMed...
    8. Klein M, Mann H, Pleštilová L, Betteridge Z, McHugh N, Remáková M, Novota P, Vencovský J. Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations. J Rheumatol 2014; 41(6): 1133-1139. Go to original source... Go to PubMed...
    9. Mann HF, Vencovsky J, Lundberg IE. Treatment-resistant inflammatory myopathy. Best Pract Res Clin Rheumatol 2010; 24(3): 427-440. Go to original source... Go to PubMed...
    10. Miller FW, Rider LG, Plotz PH, Rutkove SB, Pestronk A, Wortmann RL, Lundberg IE, Argov Z, Isenberg DA, Lacomis D, Oddis CV. Polymyositis: an overdiagnosed entity. Neurology 2004; 63: 402. Go to original source...
    11. Mohassel P, Mammen AL. The spectrum of statin myopathy. Curr Opin Rheumatol 2013; 25(6): 747-752. Go to original source... Go to PubMed...
    12. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE. RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65(2): 314-324. Go to original source... Go to PubMed...
    13. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, Sato T, Kiuchi T, Ohashi Y. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995; 22(4): 668-674. Go to PubMed...
    14. Tansley S, Gunawardena H. The Evolving Spectrum of Polymyositis and Dermatomyositis-Moving Towards Clinicoserological Syndromes: A Critical Review. Clin Rev Allergy Immunol 2013 [Epub ahead of print]. Go to original source... Go to PubMed...
    15. Targoff IN, Miller FW, Medsger TA Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997; 9(6): 527-535. Go to original source... Go to PubMed...
    16. Tomasová Studynková J, Charvát F, Jarosová K, Vencovsky J. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) 2007; 46(7): 1174-1179. Go to original source... Go to PubMed...
    17. van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, Dinant HJ, Linssen WH, Wokke JH, de Visser M. Polymyositis: an overdiagnosed entity. Neurology 2003; 61: 316-321. Go to original source... Go to PubMed...
    18. Vencovský J, Jarošová K, Machácek S, Studýnková J, Kafková J, Bartůnková J, Němcová D, Charvát F. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000; 29(2): 95-102. Go to original source... Go to PubMed...
    19. Vencovsky J.Therapeutic strategies in polymyositis and dermatomyositis. Drug Discov Today: Therapeutic Strategies 2004; 1: 369-374. Go to original source...
    20. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, Thornton BC, Burgess SH, Plotz PH, Miller FW. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998; 41(3): 392-399. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.